Burrill & Company identified more than $2.6bn in expected funding through nine healthcare initiatives announced since the end of February to end-March.

A host of new initiatives focused on funding translational research and early-stage companies brought together the public and private sector, particularly with the goal of building life sciences centers in specific locations. In all, Burrill & Company identified more than $2.6bn in expected funding through nine initiatives announced since the end of February to end-March.

The largest of these efforts, a $760m partnership between Russia’s Rusnano and the US venture capital firm Domain Associates, will invest in emerging life sciences technology companies, foster the transfer of technology into Russia, and establish manufacturing facilities in Russia for production of advanced therapeutic products. As part of the effort, Rusnano and Domain expect to co-invest in about 20 US-based healthcare technology companies.

Other initiatives include an effort by the Welsh government to create a biotech hub through an $80m commitment to what is targeted to be a $375m fund; a $100m research…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?